<DOC>
	<DOCNO>NCT02319148</DOCNO>
	<brief_summary>The primary objective study estimate effect different strong enzyme ( CYP3A4 ) inhibitor , itraconazole , diltiazem , verapamil single dose pharmacokinetics PF-00489791 healthy volunteer . The study enroll approximately 18 subject randomize 1 3 treatment group . The study also intend determine safety tolerability single-dose PF- 00489791 administer steady-state itraconazole , diltiazem , verapamil .</brief_summary>
	<brief_title>A Study Estimate Effect CYP3A4 Inhibitors ( Itraconazole , Diltiazem Verapamil ) Pharmacokinetics Single Dose PF- 00489791 Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Cytochrome P-450 CYP3A Inhibitors</mesh_term>
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<mesh_term>Verapamil</mesh_term>
	<mesh_term>Diltiazem</mesh_term>
	<criteria>Healthy male and/or female subject age 18 55 year , inclusive ( healthy define clinically relevant abnormality identify detailed medical history , full physical examination , include blood pressure pulse rate measurement , 12lead ECG clinical laboratory test ) Body Mass Index ( BMI ) 17.5 30.5 kg/m2 ; total body weight &gt; 50 kg ( 110 lb . ) personally sign date informed consent document willing able comply schedule visit , treatment plan , laboratory test , study procedure . Participating female subject nonchildbearing potential must meet least one follow criterion : achieve postmenopausal status ; undergone document hysterectomy and/or bilateral oophorectomy ; medically confirm ovarian failure . All female subject ( include female tubal ligation females NOT documented hysterectomy , bilateral oophorectomy and/or ovarian failure ) consider childbearing potential . Subjects include study : presence/ history disorder prevents study completion Evidence/history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease Any surgical medical condition may interfere absorption distribution , metabolism , excretion study drug A positive urine drug screen history regular excessive alcohol consumption use tobaccoor nicotinecontaining product excess 24hours prior admission discharge Treatment investigational drug within 30 day ( determined local requirement ) 5 halflives precede first dose study med . Out range blood pressure include current evidence orthostatic change blood pressure Abnormal ECG history current evidence clinically important cardiac conduction abnormality . Also exclude : pregnant breastfeed female subject ; male subject partner currently pregnant ; male female subject childbearing potential unwilling unable use highly effective method contraception describe protocol duration study least 28 day last dose investigational product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>